ELYM vs. XBIT, CGEN, SELB, MRNS, CUE, GYRE, IMNM, SPRY, ZNTL, and CVAC
Should you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include XBiotech (XBIT), Compugen (CGEN), Selecta Biosciences (SELB), Marinus Pharmaceuticals (MRNS), Cue Biopharma (CUE), Gyre Therapeutics (GYRE), Immunome (IMNM), ARS Pharmaceuticals (SPRY), Zentalis Pharmaceuticals (ZNTL), and CureVac (CVAC). These companies are all part of the "medical" sector.
XBiotech (NASDAQ:XBIT) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.
XBiotech has higher revenue and earnings than Eliem Therapeutics.
In the previous week, Eliem Therapeutics had 2 more articles in the media than XBiotech. MarketBeat recorded 4 mentions for Eliem Therapeutics and 2 mentions for XBiotech. XBiotech's average media sentiment score of 1.19 beat Eliem Therapeutics' score of 0.63 indicating that Eliem Therapeutics is being referred to more favorably in the news media.
55.7% of XBiotech shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 33.1% of XBiotech shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
XBiotech received 308 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 69.98% of users gave XBiotech an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote.
XBiotech's return on equity of -13.32% beat Eliem Therapeutics' return on equity.
XBiotech has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.36, suggesting that its stock price is 136% less volatile than the S&P 500.
Summary
XBiotech beats Eliem Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Eliem Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Eliem Therapeutics Competitors List
Related Companies and Tools